Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
None (32) ·
(multiple, generic dominant) (1) ·
Alfenta (1) ·
Colcrys, Mitigare, Gloperba, Lodoco (low-dose cardiovascular) (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Duragesic (1) ·
Heroin (1) ·
Krokodil (1) ·
Nubain (1) ·
Nucynta (1) ·
O-DSMT (1) ·
Opana (1) ·
Stablon (1) ·
Stadol (1) ·
Sufenta (1) ·
Talwin (1) ·
Ultiva (1) ·
Vicodin (1) ·
Zyloprim, Aloprim (IV) (1)
classes: (Click arrow to add another value)
mechanism:
uses:
None (49) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
'"`UNIQ--vote-0000030B-QINU`"', '"`UNIQ--vote-0000030C-QINU`"', '"`UNIQ--vote-0000030D-QINU`"', '"`UNIQ--vote-0000030E-QINU`"' (1) ·
'"`UNIQ--vote-00000C6D-QINU`"', '"`UNIQ--vote-00000C6E-QINU`"', '"`UNIQ--vote-00000C6F-QINU`"', '"`UNIQ--vote-00000C70-QINU`"', '"`UNIQ--vote-00000C71-QINU`"' (1)
starting dose:
None (49) ·
100 mg PO once daily; titrate by 100 mg every 2-4 weeks to a serum urate target (typically <6 mg/dL, or <5 in tophaceous disease) (1) ·
Acute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction (1) ·
Adult: 15–60 mg every 4 hours as needed. (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (49) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Limited safety data; weigh benefit individually.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Used in FMF in pregnancy; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 55 results in range #1 to #55.